Water-Soluble Vitamin And Mineral Feed Supplements Market Insights: Revenue Expected to Surpass $110.99 Billion by 2029

Uncover key drivers, emerging technologies, and competitive movements shaping the water-soluble vitamin and mineral feed supplements market from 2025–2034 with trusted insights from The Business Research Company

What Is The Current Size And Expected Growth Outlook For The Water-Soluble Vitamin And Mineral Feed Supplements Market?

The neurological disorder drugs market has shown strong growth in recent years. It is forecast to increase from $84.6 billion in 2024 to $89.24 billion in 2025, achieving a compound annual growth rate (CAGR) of 5.5%. This historical growth can be linked to factors such as increased animal testing producing promising results, a rise in therapeutic treatments, the growing incidence of neurological problems, governmental initiatives, and an increase in healthcare expenditure.

The neurological disorder drugs market size is expected to experience robust expansion in the coming years. It is projected to reach $110.99 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 5.6%. This growth during the forecast period can be attributed to the increasing array of therapeutic options and personalized therapies, a stronger focus on disease-modifying treatments, the expanding utilization of digital biomarkers, and the rising prevalence of neurological diseases. Key trends anticipated in the forecast period include progress in drug design, advancements in neuroimaging, breakthroughs in genetic research, strategic collaborations and licensing agreements, and the emergence of regenerative medicine.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

Which Growth Drivers Are Propelling The Water-Soluble Vitamin And Mineral Feed Supplements Market?

The future expansion of the neurological disorder drugs market is anticipated due to the rising occurrence of neurological diseases. These conditions, which involve structural, biochemical, or electrical irregularities affecting the brain, spinal cord, and nerves, manifest in various symptoms. The escalating incidence of neurological diseases can be linked to an aging global population and increased susceptibility to environmental, metabolic, and lifestyle risk factors. Drugs for neurological disorders are essential in managing these intricate conditions, providing symptom alleviation, slowing disease advancement, and enhancing long-term patient prognoses. For example, the Australian Institute of Health and Welfare, an Australia-based government entity, projected in September 2024 that the population affected by dementia in Australia will more than double from approximately 411,100 in 2023 to 849,300 by 2058, impacting about 315,500 men and 533,800 women. Consequently, the growing prevalence of neurological diseases is a key factor boosting the neurological disorder drugs market.

Which Segmentation Factors Are Most Significant In The Water-Soluble Vitamin And Mineral Feed Supplements Market Analysis?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

What New Opportunities Are Emerging From Trends In The Water-Soluble Vitamin And Mineral Feed Supplements Market?

Leading companies in the neurological disorder drugs market are concentrating on developing advanced Ocrelizumab drug therapies to improve treatment efficacy, enhance patient outcomes, and broaden therapeutic alternatives for individuals suffering from multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody utilized as a therapeutic agent for multiple sclerosis (MS), a type of neurological disorder. For example, in February 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, introduced Ocrevus (Ocrelizumab) in India, presenting a new disease-modifying therapy (DMT) for multiple sclerosis. Drawing on over 10 years of clinical and real-world data, Ocrevus stands as the first and only approved DMT for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). This monoclonal antibody specifically targets CD20-positive B cells, which are believed to contribute to the autoimmune assault on the central nervous system in multiple sclerosis (MS). Ocrevus is prescribed for treating both relapsing-remitting MS (RRMS) and primary progressive MS (PPMS), making it the inaugural drug approved for both forms of the illness. It is given intravenously, typically every six months, and clinical trials have demonstrated its effectiveness in lessening disease activity and slowing disability progression.

Who Are The Most Influential Companies In The Water-Soluble Vitamin And Mineral Feed Supplements Market?

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Which Region Holds The Largest Share In The Water-Soluble Vitamin And Mineral Feed Supplements Market Today?

North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=17207&type=smp

Browse Through More Reports Similar to the Global Water-Soluble Vitamin And Mineral Feed Supplements Market 2025, By The Business Research Company

Rare Neurological Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Neurological Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

Hpv Associated Disorders Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hpv-associated-disorders-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795